Effect of Antiepileptic Agent, Levetiracetam, on Urodynamic Parameters and Neurogenic Bladder Overactivity in Chronically Paraplegic Rats

Urology

Volumn 73, Issue 4, 2009, Pages 922-927

  Elzayat, Ehab A ^a   Campeau, Lysanne ^a   Karsenty, Gilles ^a   Blok, Bertil ^a   Padjen, Ante L ^a   Corcos, Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ETIRACETAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLADDER PRESSURE; CONTROLLED STUDY; CYSTOMETRY; DRUG EFFECT; FEMALE; MORBIDITY; NONHUMAN; OSMOTIC MINIPUMP; OVERACTIVE BLADDER; PARAPLEGIA; PRIORITY JOURNAL; RAT; SPINAL CORD TRANSSECTION; URODYNAMICS;

ANIMALS; ANTICONVULSANTS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; PARAPLEGIA; PIRACETAM; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER, NEUROGENIC; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

EID: 63149161672     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.10.056     Document Type: Article

References (17)

1. Chapple C., Yamanishi T., and Chess-Williams R. Muscarinic receptor subtypes and management of the overactive bladder. Urology 60 (2002) 82-88
2. Steers W.D. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 4 (2002) S7-S18
3. Andersson K. Advances in the pharmacological control of the bladder. Exp Physiol 84 (1999) 195-213
4. Andersson K.E. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology 63 suppl 1 (2004) 32-41
5. Carbone A., Palleschi G., Conte A., et al. Gabapentin treatment of neurogenic overactive bladder. Clin Neuropharmacol 29 (2006) 206-214
6. Kim Y.T., Kwon D.D., Kim J., et al. Gabapentin for overactive bladder and nocturia after anticholinergic failure. Int Braz J Urol 30 (2004) 275-278
7. Stefan H., and Feuerstein T.J. Novel anticonvulsant drugs. Pharmacol Ther 113 (2007) 165-183
8. Ardid D., Lamberty Y., Alloui A., et al. Antihyperanalgesic effect of levetiracetam in neuropathic pain models in rats. Eur J Pharmacol 473 (2003) 27-33
9. Price M.J. Levetiracetam in the treatment of neuropathic pain: three case studies. Clin J Pain 20 (2004) 33-36
10. Shorvon S.D., Lowenthal A., Janz D., et al., European Levetiracetam Study Group. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 41 (2000) 1179-1186
11. Stanfa L.C., Singh L., Williams R.G., et al. Gabapentin, ineffective in normal rats, markedly reduces C-fibre evoked responses after inflammation. Neuroreport 8 (1997) 587-590
12. Sasaki K., Smith C.P., Chuang Y.C., et al. Oral gabapentin (Neurontin) treatment of refractory genitourinary tract pain. Tech Urol 7 (2001) 47-49
13. Bayer K., Ahmadi S., and Zeilhofer H.U. Gabapentin may inhibit synaptic transmission in the mouse spinal cord dorsal horn through a preferential block of P/Q-type Ca2+ channels. Neuropharmacology 46 (2004) 743-749
14. Lukyanetz E.A., Shkryl V.M., and Kostyuk P.G. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 43 (2002) 9-18
15. Madeja M., Margineanu D.G., Gorji A., et al. Reduction of voltage-operated potassium currents by levetiracetam: a novel antiepileptic mechanism of action?. Neuropharmacology 45 (2003) 661-671
16. Poulain P., and Margineanu D.G. Levetiracetam opposes the action of GABA antagonists in hypothalamic neurons. Neuropharmacology 42 (2002) 346-352
17. Ben-Menachem E., Falter U., and European Levetiracetam Study Group. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. Epilepsia 41 (2000) 1276-1283